Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Anti-cytokine therapy and small molecule agents for the treatment of inflammatory bowel disease

Anti-cytokine therapy and small molecule agents for the treatment of inflammatory bowel disease Inflammatory bowel disease (IBD), including Crohn disease and ulcerative colitis, with multifactorial etiologies has led to a global health-associated burden in many countries. Substantial efforts are devoted to understand the pathogenesis, behavioral and environmental triggers, which may be specifically valuable for the treatment of IBD. The specific pathogenesis underlying IBD is as yet incompletely understood. The use of anti-cytokine therapy and small molecule agents targeting the immune system is thought to restore the body’s intestinal barrier function and relieve inflammation with manageable adverse effects. In this review, we report recent advances in anti-cytokine therapy and treatment with small molecule agents for the management of IBD. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Cytokine Network Springer Journals

Anti-cytokine therapy and small molecule agents for the treatment of inflammatory bowel disease

Download PDF
10 pages

Loading next page...
 
/lp/springer-journals/anti-cytokine-therapy-and-small-molecule-agents-for-the-treatment-of-5S5pRuCfds
Publisher
Springer Journals
Copyright
Copyright © JLE/Springer 2021
eISSN
1952-4005
DOI
10.1684/ecn.2021.0472
Publisher site
See Article on Publisher Site

Abstract

Inflammatory bowel disease (IBD), including Crohn disease and ulcerative colitis, with multifactorial etiologies has led to a global health-associated burden in many countries. Substantial efforts are devoted to understand the pathogenesis, behavioral and environmental triggers, which may be specifically valuable for the treatment of IBD. The specific pathogenesis underlying IBD is as yet incompletely understood. The use of anti-cytokine therapy and small molecule agents targeting the immune system is thought to restore the body’s intestinal barrier function and relieve inflammation with manageable adverse effects. In this review, we report recent advances in anti-cytokine therapy and treatment with small molecule agents for the management of IBD.

Journal

European Cytokine Network – Springer Journals

Published: Dec 1, 2021

Keywords: inflammatory bowel disease; cytokines; small molecule therapy

References

  • Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
    Ng, SC; Shi, HY; Hamidi, N
  • The epidemiology of inflammatory bowel disease: East meets west
    Mak, WY; Zhao, M; Ng, SC; Burisch, J
  • The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  • The global burden of IBD: from 2015 to 2025
    Kaplan, GG
  • Incidence and phenotype of inflammatory bowel disease based on results from the Asiapacific Crohn’s and colitis epidemiology study
    Ng, SC; Tang, W; Ching, JY
  • Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study
    Adamiak, T; Walkiewicz-Jedrzejczak, D; Fish, D
  • Inflammatory Bowel Disease in Children and Adolescents
    Rosen, MJ; Dhawan, A; Saeed, SA
  • Pharmacological Autophagy Regulators as Therapeutic Agents for Inflammatory Bowel Diseases
    Retnakumar, SV; Muller, S
  • Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function
    Schoultz, I; Keita, V
  • Epidemiology and risk factors for IBD
    Ananthakrishnan, AN
  • Elective Abdominal Surgery for Inflammatory Bowel Disease
    Feinberg, AE; Valente, MA
  • ACG Clinical Guideline: Management of Crohn’s Disease in Adults
    Lichtenstein, GR; Loftus, EV; Isaacs, KL; Regueiro, MD; Gerson, LB; Sands, BE
  • European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease
    Doherty, G; Katsanos, KH; Burisch, J
  • JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
    Schwartz, DM; Kanno, Y; Villarino, A; Ward, M; Gadina, M; O’Shea, JJ
  • Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target
    Sukocheva, OA; Furuya, H; Ng, ML
  • Sphingosine-1-phosphate receptor-1 (S1P(1)) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease
    Karuppuchamy, T; Behrens, EH; Gonzalez-Cabrera, P
  • Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
    Levin, AD; Wildenberg, ME; van den Brink, GR
  • Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflamm Bowel Dis
    Ungar, B; Levy, I; Yavne, Y
  • Checkpoints in TNF-Induced Cell Death: Implications in Inflammation and Cancer
    Annibaldi, A; Meier, P
  • Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease
    Murch, SH; Lamkin, VA; Savage, MO; Walker-Smith, JA; MacDonald, TT
  • Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future
    Berns, M; Hommes, DW
  • Molecular mechanism of action of anti-tumor necrosis factor antibodies in Inflammatory Bowel Disease
    Billmeier, U; Dieterich, W; Neurath, MF; Atreya, R
  • Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn’s Disease
    Papamichael, K; Cheifetz, AS
  • Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation
    Duricova, D; Dvorakova, E; Hradsky, O
  • Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study
    Moens, A; van der Woude, CJ; Julsgaard, M
  • Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants
    Kattah, MG; Milush, JM; Burt, T
  • Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
    Horneff, G; Seyger, MMB; Arikan, D
  • Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn’s Disease, Based on a Pooled Analysis of Data From Clinical Trials
    Loftus, EV; Colombel, JF; Schreiber, S
  • Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn’s Disease
    Walters, TD; Faubion, WA; Griffiths, AM
  • Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan
    Tajiri, H; Motoya, S; Kinjo, F
  • Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
    Jørgensen, KK; Olsen, IC; Goll, GL
  • Switching from infliximab originator to a first biosimilar is safe and effective. Results of a case-control study with drug levels and antibodies evaluation
    Guiotto, C; Italia, A; Lavagna, A
  • Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort
    Gonczi, L; Gecse, KB; Vegh, Z
  • Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study
    Guerra, I; Perez-Jeldres, T; Iborra, M
  • A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab
    Scheinfeld, N
  • Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases
    Taylor, PC
  • Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
    Lichtenstein, GR; Feagan, BG; Cohen, RD
  • Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease
    Singh, S; Fumery, M; Sandborn, WJ; Murad, MH
  • Assessing response and loss of response to biological therapies in IBD
    Yanai, H; Hanauer, SB
  • Incidence and Predictors of Success of Adalimumab Dose Escalation and Deescalation in Ulcerative Colitis: a Real-World Belgian Cohort Study
    Van de Vondel, S; Baert, F; Reenaers, C
  • Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn’s Disease
    Srinivasan, A; Vasudevan, A; McFarlane, A; Sparrow, MP; Gibson, PR; Van Langenberg, DR
  • Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study
    Kennedy, NA; Heap, GA; Green, HD
  • HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
    Sazonovs, A; Kennedy, NA; Moutsianas, L
  • Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
    Zeissig, S; Rosati, E; Dowds, CM
  • Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflamm Bowel Dis
    Ungar, B; Kopylov, U; Yavzori, M
  • Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Sands, BE; Peyrin-Biroulet, L; Loftus, EV
  • Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease
    Lamb, CA; O’Byrne, S; Keir, ME; Butcher, EC
  • Vedolizumab as induction and maintenance therapy for Crohn’s disease
    Sandborn, WJ; Feagan, BG; Rutgeerts, P
  • Vedolizumab as induction and maintenance therapy for ulcerative colitis
    Feagan, BG; Rutgeerts, P; Sands, BE
  • Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed
    Sands, BE; Feagan, BG; Rutgeerts, P
  • Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
    Sandborn, WJ; Colombel, JF; Panaccione, R
  • Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
    Feagan, BG; Patel, H; Colombel, JF
  • Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with Inflamm Bowel Dis
    Singh, S; Dulai, PS; Vande Casteele, N
  • Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials
    Feagan, BG; Sandborn, WJ; Colombel, JF
  • Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn’s Disease: A Post Hoc Analysis of GEMINI 2 and 3
    Sands, BE; Van Assche, G; Tudor, D; Akhundova-Unadkat, G; Curtis, RI; Tan, T
  • Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort
    Tadbiri, S; Peyrin-Biroulet, L; Serrero, M
  • Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease
    Kotze, PG; Ma, C; Almutairdi, A
  • Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab
    Favale, A; Onali, S; Caprioli, F
  • Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study
    Hupé, M; Rivière, P; Nancey, S
  • Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn’s disease
    Bohm, M; Xu, R; Zhang, Y
  • Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting
    Ng, SC; Hilmi, IN; Blake, A
  • Outcome of Pregnancies in Female Patients With Inflamm Bowel Dis Treated With Vedolizumab
    Moens, A; van Hoeve, K; Humblet, E
  • Functional involvement of P-selectin and MAdCAM-1 in the recruitment of alpha4beta7-integrin-expressing monocyte-like cells to the pregnant mouse uterus
    Fernekorn, U; Butcher, EC; Behrends, J; Hartz, S; Kruse, A
  • Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease
    Conrad, MA; Stein, RE; Maxwell, EC
  • Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?
    Argollo, MC; Allocca, M; Furfaro, F; Peyrin-Biroulet, L; Danese, S
  • New treatment options for Inflammatory Bowel Disease
    Verstockt, B; Ferrante, M; Vermeire, S; Van Assche, G
  • Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
    Sands, BE; Sandborn, WJ; Panaccione, R
  • Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
    Feagan, BG; Sandborn, WJ; Gasink, C
  • Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease
    Rutgeerts, P; Gasink, C; Chan, D
  • IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease
    Hanauer, SB; Sandborn, WJ; Feagan, BG
  • Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study
    Rowan, CR; Keegan, D; Byrne, K
  • First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
    Singh, S; Murad, MH; Fumery, M; Dulai, PS; Sandborn, WJ
  • The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn’s disease refractory to anti-tumour necrosis factor
    Alric, H; Amiot, A; Kirchgesner, J
  • Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment
    Biemans, VBC; van der Woude, CJ; Dijkstra, G
  • British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
    Lamb, CA; Kennedy, NA; Raine, T
  • Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
    Biemans, VBC; van der Meulen-de Jong, AE; van der Woude, CJ
  • Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study
    Feagan, BG; Panés, J; Ferrante, M
  • Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study
    Feagan, BG; Sandborn, WJ; D’Haens, G
  • Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease
    Almradi, A; Hanzel, J; Sedano, R
  • Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    Papp, KA; Blauvelt, A; Bukhalo, M
  • JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
    Owen, KL; Brockwell, NK; Parker, BS
  • Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More
    Misselwitz, B; Juillerat, P; Sulz, MC; Siegmund, B; Brand, S
  • Small molecule oral targeted therapies in ulcerative colitis
    Shivaji, UN; Nardone, OM; Cannatelli, R; Smith, SC; Ghosh, S; Iacucci, M
  • JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications
    Agrawal, M; Kim, ES; Colombel, JF
  • Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
    Sands, BE; Armuzzi, A; Marshall, JK
  • Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
    Sandborn, WJ; Su, C; Sands, BE
  • Real-World Experience with Tofacitinib in IBD at a Tertiary Center
    Weisshof, R; Aharoni Golan, M; Sossenheimer, PH
  • Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
    Biemans, VBC; Sleutjes, JAM; de Vries, AC
  • Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial
    Mukherjee, A; Hazra, A; Smith, MK
  • Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4. 4 Years of Data From Global Clinical Trials
    Sandborn, WJ; Panés, J; D’Haens, GR
  • Safety of Janus Kinase Inhibitors in Patients With Inflamm Bowel Dis or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
    Olivera, PA; Lasa, JS; Bonovas, S; Danese, S; Peyrin-Biroulet, L
  • Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions
    Gonzalez-Cabrera, PJ; Jo, E; Sanna, MG
  • Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study
    Feagan, BG; Sandborn, WJ; Danese, S
  • Ozanimod: First Approval
    Lamb, YN
  • Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
    Sandborn, WJ; Feagan, BG; Wolf, DC
  • Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
    Sandborn, WJ; Peyrin-Biroulet, L; Zhang, J
  • Knockdown of Smad7 With a Specific Antisense Oligonucleotide Attenuates Colitis and Colitis-Driven Colonic Fibrosis in Mice
    Izzo, R; Bevivino, G; De Simone, V
  • Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn’s disease
    Ardizzone, S; Bevivino, G; Monteleone, G
  • Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease
    Monteleone, G; Neurath, MF; Ardizzone, S
  • Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn’s disease
    Monteleone, G; Di Sabatino, A; Ardizzone, S
  • Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn’s Disease
    Feagan, BG; Sands, BE; Rossiter, G
  • Mongersen (GED-0301) for Active Crohn’s Disease: Results of a Phase 3 Study
    Sands, BE; Feagan, BG; Sandborn, WJ
  • Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders
    Bhat, A; Ray, B; Mahalakshmi, AM
  • Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
    Li, H; Zuo, J; Tang, W
  • Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives
    Sakkas, LI; Mavropoulos, A; Bogdanos, DP
  • Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis
    Danese, S; Neurath, MF; Kopofi, A
  • Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis
    Torres, T; Puig, L
  • Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
    Friedrich, M; Pohin, M; Powrie, F